Fresenius Medical Care AG (ETR:FME - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of €38.19 ($39.37) and traded as high as €44.31 ($45.68). Fresenius Medical Care shares last traded at €44.16 ($45.53), with a volume of 149,457 shares.
Fresenius Medical Care Price Performance
The stock's 50-day moving average price is €42.03 and its 200 day moving average price is €38.22. The company has a quick ratio of 0.80, a current ratio of 1.46 and a debt-to-equity ratio of 77.56. The firm has a market capitalization of $12.96 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 0.42 and a beta of 0.86.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Stories
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
